Accessibility Menu
Jyong Biotech logo

Jyong Biotech(NASDAQ) MENS

Market Cap$180.39MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2025)-77%
5 YearN/A
1 Year-82%
1 Month+29%
$2.44
+3.39%
+0.08Today
Jyong Biotech last closing stock price
MetricPriceDate
Last closeUSD 2.432026-07-27
Jyong Biotech stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+4.74%USD 2.322026-07-20
1 month+29.26%USD 1.882026-06-26
3 month+11.98%USD 2.172026-04-28
Year to date-38.48%USD 3.952025-12-31
1 year-82.39%USD 13.802025-07-25
Since inception-76.66%USD 10.112025-06-17

Jyong Biotech Financials at a Glance

Market Cap

$180.39MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$4.67M

EPS (TTM)

-$0.06

P/E Ratio

-38.27

Dividend

$0.00

Beta (Volatility)

5.01 (High)

Price

$2.44

Volume

796

Open

$2.45

Previous Close

$2.44

Daily Range

$2.44 - $2.46

52-Week Range

$1.43 - $67.00

Estimated Earnings Date

N/A

MENS News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Jyong Biotech

Jyong Biotech Ltd. is a Taiwanese biotechnology company focused on developing botanical therapeutics for urinary system diseases. The company operates through subsidiaries and is advancing a promising pipeline of drug candidates.

Products and Services
  • Development of botanical therapeutics for urinary system diseases
  • Key drug candidates include MCS-2 for benign prostatic hyperplasia
  • PCP for prostate cancer and IC in pre-clinical stages
Growth Outlook
  • Pipeline includes multiple candidates in various stages of development
  • Potential market expansion as urinary health awareness increases
  • Strategic partnerships may enhance research and development capabilities
Financial Highlights
  • Recent quarterly net income of -$3.42 million, reflecting ongoing R&D investments
  • Trailing twelve months (TTM) P/E ratio of -27.28 indicates potential for future growth
  • Cash and short-term investments totaled $1.18 million as of Q4 2025
Jyong Biotech Ltd. is positioned in the biotechnology sector, focusing on innovative solutions for urinary health. The company’s commitment to research and development is evident in its active pipeline, which includes candidates at various stages of clinical trials. The potential for growth is supported by increasing awareness of urinary health issues and the strategic direction of the company. Financially, while the company has reported net losses, the focus on R&D suggests a long-term vision aimed at capturing market opportunities. The current cash position provides a foundation for continued operations and development efforts.
AI Generated • Jul 25, 2026

Industry

Biotechnology

Sector

Health Care

Employees

27

CEO

Fu-Feng Kuo, MBA

Headquarters

New Taipei City, TP 221, TW

MENS Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

19.39%

Return on Capital

N/A

Return on Assets

-22.49%

Earnings Yield

-2.61%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$180.39MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

74.23M

Volume

796

Avg. Volume

92.04K

Financials (TTM)

Gross Profit

-$58.00K

Operating Income

-$2.61M

EBITDA

-$2.63M

Operating Cash Flow

-$851.00

Capital Expenditure

$0.00

Free Cash Flow

-$851.00

Cash & ST Invst.

$1.18M

Total Debt

$18.55M

Jyong Biotech Performance Analysis

Jyong Biotech annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Jyong Biotech sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-31N/A
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Jyong Biotech annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.0957.8%
20232023-12-31USD -0.06-36.0%
20242024-12-31USD -0.04-31.4%
20252025-12-31USD -0.0657.2%
Jyong Biotech sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-31N/A
Q22025-06-30N/A
Q32025-09-30-32.2%
Q42025-12-31-100.4%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$180.39MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$6.68M

N/A

Employees

27

N/A

Net Income

-$3.42M

-403798.4%

EBITDA

-$1.79M

-342020.3%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Total Cash

$1.18M

+1102.0%

Total Debt

$18.55M

+2.3%

Accounts Receivable

$13.51M

N/A

Inventory

$0.00

N/A

Long Term Debt

$10.19M

-4.8%

Short Term Debt

$8.36M

+12.4%

Return on Assets

-22.49%

N/A

Return on Invested Capital

18.59%

N/A

Free Cash Flow

$0.00

+100.0%

Operating Cash Flow

$0.00

+100.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
AAPGAscentage Pharma Group International
$18.89+3.28%
RAREUltragenyx Pharmaceutical Inc.
$26.89-0.04%
LEGNLegend Biotech Corporation
$19.27-13.28%
CELCCelcuity Inc.
$82.27-0.42%

Trending Stocks

Symbol / CompanyPricePrice Chg
JBLUJetBlue Airways
$5.38+0.02%
MUUDirexion Shares ETF Trust - Direxion Daily Mu Bull 2x Shares
$29.92-0.04%
TQQQProShares Trust - ProShares UltraPro Qqq
$63.40-0.01%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$45.22+0.01%

Questions About MENS

What is the current price of Jyong Biotech?

Jyong Biotech is trading at $2.44 per share.

What is the 52-week range for Jyong Biotech?

Over the past 52 weeks, Jyong Biotech has traded between $1.43 and $67.00.

How much debt does Jyong Biotech have?

As of the most recent reporting period, Jyong Biotech reported total debt of $18.55M.

How much cash does Jyong Biotech have on hand?

Jyong Biotech reported $1.18M in cash and cash equivalents in its most recent financial results.

What is Jyong Biotech’s dividend yield?

Jyong Biotech does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services